{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T12:12:00Z","timestamp":1790683920992,"version":"4.1.0"},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,9,1]]},"DOI":"10.2169\/internalmedicine.4887-24","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:12:29Z","timestamp":1740157949000},"page":"2592-2596","source":"Crossref","is-referenced-by-count":1,"title":["Anamorelin Induced Hyperglycemia in a Patient with Type 1 Diabetes by Stimulating Growth Hormone Secretion"],"prefix":"10.2169","volume":"64","author":[{"given":"Kenta","family":"Okuro","sequence":"first","affiliation":[{"name":"Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Morita","sequence":"additional","affiliation":[{"name":"Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Noshi","sequence":"additional","affiliation":[{"name":"Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moe","family":"Kusushita","sequence":"additional","affiliation":[{"name":"Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Ochiai","sequence":"additional","affiliation":[{"name":"Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Utsu","sequence":"additional","affiliation":[{"name":"Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soji","family":"Kasayama","sequence":"additional","affiliation":[{"name":"Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kunihiko","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Nippon Life Hospital, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Shiiya T, Nakazato M, Mizuta M, et al. Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87: 240-244, 2002.","DOI":"10.1210\/jc.87.1.240"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Takaya K, Ariyasu H, Kanamoto N, et al. Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 85: 4908-4911, 2000.","DOI":"10.1210\/jc.85.12.4908"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Nakazato M, Murakami N, Date Y, et al. A role for ghrelin in the central regulation of feeding. Nature 409: 194-198, 2001.","DOI":"10.1038\/35051587"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Garcia JM. What is next after anamorelin? Curr Opin Support Palliat Care 11: 266-271, 2017.","DOI":"10.1097\/SPC.0000000000000299"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Temel JS, Abernethy AP, Currow DC, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol 17: 519-531, 2016.","DOI":"10.1016\/S1470-2045(15)00558-6"},{"key":"6","doi-asserted-by":"publisher","unstructured":"6. Katakami N, Uchino J, Yokoyama T, et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 124: 606-616, 2018.","DOI":"10.1002\/cncr.31128"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ando K, Naito T, Hamauchi S, et al. The efficacy and safety of anamorelin among patients with diabetes. Int J Clin Oncol 29: 1115-1121, 2024.","DOI":"10.1007\/s10147-024-02546-8"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Yamamoto J, Onodera H, Kaminaga Y, Kayaba Y, Usui M. Anamorelin induced acute hyperglycemia in a patient with advanced pancreatic cancer and diabetes: a case report. Tohoku J Exp Med 262: 263-268, 2024.","DOI":"10.1620\/tjem.2024.J013"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Yada T, Damdindorj B, Rita RS, et al. Ghrelin signalling in \u03b2-cells regulates insulin secretion and blood glucose. Diabetes Obes Metab 16 (Suppl 1): 111-117, 2014.","DOI":"10.1111\/dom.12344"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Chuang JC, Sakata I, Kohno D, et al. Ghrelin directly stimulates glucagon secretion from pancreatic alpha-cells. Mol Endocrinol 25: 1600-1611, 2011.","DOI":"10.1210\/me.2011-1001"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Vestergaard ET, Gormsen LC, Jessen N, et al. Ghrelin infusion in humans induces acute insulin resistance and lipolysis independent of growth hormone signaling. Diabetes 57: 3205-3210, 2008.","DOI":"10.2337\/db08-0025"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kim SH, Park MJ. Effects of growth hormone on glucose metabolism and insulin resistance in human. Ann Pediatr Endocrinol Metab 22: 145-152, 2017.","DOI":"10.6065\/apem.2017.22.3.145"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Schwarz JM, Mulligan K, Lee J, et al. Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 87: 942, 2002.","DOI":"10.1210\/jc.87.2.942"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kilgour E, Baldwin SA, Flint DJ. Divergent regulation of rat adipocyte GLUT1 and GLUT4 glucose transporters by GH. J Endocrinol 145: 27-33, 1995.","DOI":"10.1677\/joe.0.1450027"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. LeRoith D, Yakar S. Mechanisms of disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nat Clin Pract Endocrinol Metab 3: 302-310, 2007.","DOI":"10.1038\/ncpendmet0427"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nambam B, Schatz D. Growth hormone and insulin-like growth factor-I axis in type 1 diabetes. Growth Horm IGF Res 38: 49-52, 2018.","DOI":"10.1016\/j.ghir.2017.12.005"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Garcia JM, Polvino WJ. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers. Growth Horm IGF Res 19: 267-273, 2009.","DOI":"10.1016\/j.ghir.2008.12.003"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Hunter WM, Willoughby JM, Strong JA. Plasma insulin and growth hormone during 22-hour fasts and after graded glucose loads in six healthy adults. J Endocrinol 40: 297-311, 1968.","DOI":"10.1677\/joe.0.0400297"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Petrossians P, Daly AF, Natchev E, et al. Acromegaly at diagnosis in 3173 patients from the Li\u00e8ge Acromegaly Survey (LAS) Database. Endocr Relat Cancer 24: 505-518, 2017.","DOI":"10.1530\/ERC-17-0253"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Kasayama S, Otsuki M, Takagi M, et al. Impaired \u03b2-cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in acromegalic patients. Clin Endocrinol (Oxf) 52: 549-555, 2000.","DOI":"10.1046\/j.1365-2265.2000.00986.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Takeda T, Sasaki T, Okamoto T, et al. Impact of the extent of weight loss before administration on the efficacy of anamorelin in advanced pancreatic cancer patients with cachexia. Intern Med 62: 1887-1893, 2023.","DOI":"10.2169\/internalmedicine.0730-22"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Naito T, Uchino J, Kojima T, et al. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index. Cancer 128: 2025-2035, 2022.","DOI":"10.1002\/cncr.34154"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Garcia JM, Friend J, Allen S. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study. Support Care Cancer 21: 129-137, 201.","DOI":"10.1007\/s00520-012-1500-1"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/17\/64_4887-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,6]],"date-time":"2025-09-06T03:25:16Z","timestamp":1757129116000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/17\/64_4887-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":23,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.4887-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"article-number":"4887-24"}}